Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Transparency in economic evaluations.

Literature DB >> 16235971

Transparency in economic evaluations.

Suzanne Hill.

Abstract

Mesh：

Year: 2005 PMID： 16235971 DOI： 10.2165/00019053-200523100-00001

Source DB: PubMed Journal: Pharmacoeconomics ISSN： 1170-7690 Impact factor: 4.981

× No keyword cloud information.

13 in total

1. Evaluation of conflict of interest in economic analyses of new drugs used in oncology.

Authors: M Friedberg; B Saffran; T J Stinson; W Nelson; C L Bennett
Journal: JAMA Date: 1999-10-20 Impact factor: 56.272

2. Quality of economic evaluations in health care.

Authors: Tom Jefferson; Vittorio Demicheli
Journal: BMJ Date: 2002-02-09

Review 3. Quantitative analysis of sponsorship bias in economic studies of antidepressants.

Authors: C Bruce Baker; Michael T Johnsrud; M Lynn Crismon; Robert A Rosenheck; Scott W Woods
Journal: Br J Psychiatry Date: 2003-12 Impact factor: 9.319

Review 4. Pharmaceutical industry sponsorship and research outcome and quality: systematic review.

Authors: Joel Lexchin; Lisa A Bero; Benjamin Djulbegovic; Otavio Clark
Journal: BMJ Date: 2003-05-31

5. Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?

Authors: Bodil Als-Nielsen; Wendong Chen; Christian Gluud; Lise L Kjaergard
Journal: JAMA Date: 2003-08-20 Impact factor: 56.272

6. Being economical with the truth: how to make your idea appear cost effective.

Authors: S Goodacre; C McCabe
Journal: Emerg Med J Date: 2002-07 Impact factor: 2.740

Review 7. Pharmacoeconomics.

Authors: Jaya Ahuja; Madhur Gupta; Ajay Kumar Gupta; Kamlesh Kohli
Journal: Natl Med J India Date: 2004 Mar-Apr Impact factor: 0.537

8. Reimbursement of glitazones in treatment of type 2 diabetes patients in Denmark in the context of a voluntary system for submitting pharmacoeconomic studies.

Authors: Hindrik Vondeling; Peter Bindslev Iversen
Journal: Eur J Health Econ Date: 2004-10

Transparency in economic evaluations.

1. Evaluation of conflict of interest in economic analyses of new drugs used in oncology.

2. Quality of economic evaluations in health care.

Review 3. Quantitative analysis of sponsorship bias in economic studies of antidepressants.

Review 4. Pharmaceutical industry sponsorship and research outcome and quality: systematic review.

5. Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?

6. Being economical with the truth: how to make your idea appear cost effective.

Review 7. Pharmacoeconomics.

8. Reimbursement of glitazones in treatment of type 2 diabetes patients in Denmark in the context of a voluntary system for submitting pharmacoeconomic studies.

Review 9. Common methodological flaws in economic evaluations.

Review 10. Economic evaluation of pharmaceuticals. Frankenstein's monster or vampire of trials?

1. Reporting pharmacoeconomic evaluations.

Review 2. A review of health care models for coronary heart disease interventions.

3. Meandering down the road to transparency.